Alzheimer's disease (AD) is a common neurodegenerative disease featured by the abnormal cerebral deposition and cognitive dysfunctions.1 Current therapeutic agents for clinical or preclinical AD treatment include: 1) cholinergic drugs with the aim of compensating the loss of neurotransmitter, 2) brain‐derived neurotrophic factors (BDNF) to protect damaged neurons, and 3) therapeutic genes to eliminate or inhibit protein aggregation. This evidence concerns the gene BDNF and neurodegenerative disease.